Clinical trials: SARS-COV2
COVID-19
A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Nirmatrelvir/Ritonavir) for the possible treatment of COVID-19.
- Trial name
- NCT05438602
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 84 sites in United States, Australia and 7 more
- Volunteers
- 158 people
- Sponsor
- Pfizer
COVID-19, Viral Respiratory Illnesses
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2…
- Trial name
- NCT04359680
- Testing
- Nitazoxanide, Vitamin Super B-Complex
- Where
- 26 sites in United States
- Volunteers
- 1,407 people
- Sponsor
- Romark Laboratories L.C.
Long COVID, Long Covid19
RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms
This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent…
- Trial name
- RECOVER-VITAL (NCT05595369)
- Testing
- Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing
- Where
- 69 sites in United States, Puerto Rico
- Volunteers
- 963 people
- Sponsor
- Kanecia Obie Zimmerman
COVID-19
PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of PF-07304814 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780541
- Testing
- PF-07304814, Remdesivir
- Where
- 40 sites in United States, Denmark
- Volunteers
- 58 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (SARS-CoV-2) from…
- Trial name
- APLICOV-PC (NCT04382066)
- Testing
- Plitidepsin 1.5 mg/day, Plitidepsin 2.0 mg/day, Plitidepsin 2.5 mg/day
- Where
- 13 sites in Spain
- Volunteers
- 46 people
- Sponsor
- PharmaMar
Covid19
To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants
This is a randomized (1:1), double-blind, placebo-controlled phase 2 study to assess safety and efficacy of Total TQ Formula (3 g daily dose of Nigella Sativa Oil) capsules versus placebo in treating patients who have tested…
- Trial name
- BOSS (NCT04914377)
- Testing
- TQ Formula/Tab
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Novatek Pharmaceuticals
Coronavirus, Coronavirus Infection
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate…
- Conditions
- Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia
- Trial name
- CYNKCOVID (NCT04365101)
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Celularity Incorporated
COVID-19
AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19
In this first-in-humans dose escalation study, AZD7442 (AZD8895 + AZD1061) will be evaluated for safety, tolerability, pharmacokinetics, and generation of anti-drug antibodies (ADAs).
- Trial name
- NCT04507256
- Testing
- AZD7442
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Corona Virus Infection, Acute Respiratory Distress Syndrome
Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
Study Objective: 1. To test if post-exposure prophylaxis with hydroxychloroquine can prevent symptomatic COVID-19 disease after known exposure to the SARS-CoV-2 coronavirus. 2.
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection, Coronavirus
- Trial name
- COVID-19 PEP (NCT04308668)
- Testing
- Hydroxychloroquine
- Where
- 5 sites in United States, Canada
- Volunteers
- 1,312 people
- Sponsor
- University of Minnesota
COVID-19, Kidney Transplant
COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study
An open label, non-randomized pilot study in kidney transplant recipients who received a completed primary series and bivalent booster of mRNA based COVID-19 vaccine and have ≤2500 U/mL SARS-CoV-2 S antibody concentration using…
- Trial name
- CPAT-SG (NCT05518487)
- Testing
- Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2 Infection, COVID-19
Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age
This study will assess the safety and immunogenicity of a fourth dose (booster) of BNT162b2 when coadministered with SIIV compared to separate administration of the vaccines when given 1 month apart (SIIV followed by BNT162b2)…
- Trial name
- NCT05310084
- Testing
- BNT162b2, Seasonal Inactivated Influenza Vaccine
- Where
- 26 sites in Australia, New Zealand
- Volunteers
- 1,134 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Covid19
A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)
COVID-19 morbidity and mortality has been associated with Cytokine Release Syndrome (CRS) and Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT04481685
- Testing
- ATI-450
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Kansas Medical Center
COVID-19
Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
This is open-labe randomized multicenter comparative Phase III study conducted in 5 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir compared with the Standard of care (SOC) in…
- Trial name
- NCT04542694
- Testing
- Favipiravir, Standard of care
- Where
- 5 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Promomed, LLC
Covid19
Endocrine, Metabolic and Microbiome Influence on the Post-acute Sequelae SARS-CoV-2 (PASC)
The aim of this study is characterize the endocrine, metabolic and microbiomes of patients with post-acute sequelae SARS-CoV-2 infection (PASC) and patients that have recovered from COVID without lingering symptoms.
- Trial name
- NCT04860869
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Covid-19
Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma
The investigators hypothesize that use of convalescent plasma donated from individuals recovered from Coronavirus Disease 2019 (COVID-19) will help expedite recovery of individuals with active, severe COVID-19 infection.
- Trial name
- Inova-CCP (NCT04502472)
- Testing
- Convalescent plasma transfusion
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Inova Health Care Services
COVID-19 Disease
A Study of LAM-002A for the Prevention of Progression of COVID-19
This is a clinical trial to evaluate the efficacy of LAM-002A compared to placebo treatment in adults with a confirmed SARS-CoV-2 infection who are receiving standards supportive care in an outpatient setting.
- Trial name
- NCT04446377
- Testing
- Apilimod Dimesylate Capsule
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- IRulya Therapeutics Inc.
Antithrombin III Deficiency, Covid19
Antithrombin III in Infectious Disease Caused by COVID-19
The purpose of this research study is to see if participants who have SARS-CoV-2 and low levels of AT3 in the blood will benefit by being given AT3.
- Trial name
- NCT04899232
- Testing
- Antithrombin III
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Enrique Ginzburg
SARS-CoV-2
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
This is a study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, and mRNA-1273.231 administered as…
- Trial name
- NCT04927065
- Testing
- mRNA-1273.211, mRNA-1273, mRNA-1273.617.2
- Where
- 23 sites in United States
- Volunteers
- 5,161 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza, Human, COVID-19
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza
Substudy A: This is a Phase 1 randomized, open-label study to describe the safety and immunogenicity of up to 3 dose- level combinations of modRNA quadrivalent influenza vaccine (qIRV (22/23)) and bivalent BNT162b2 (original/Omi…
- Trial name
- NCT05596734
- Testing
- bivalent BNT162b2 (original/Omi BA.4/BA.5), qIRV (22/23), QIV
- Where
- 59 sites in United States
- Volunteers
- 1,019 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of MP0420 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780463
- Testing
- MP0420, Remdesivir
- Where
- 105 sites in United States, Denmark and 8 more
- Volunteers
- 485 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)